A Golden Ticket to Breakthrough: Singzyme’s Bioconjugation Platform Set to Revolutionize Medicine

Singapore has just witnessed a pivotal moment in its biotechnology landscape, as local startup Singzyme proudly announced its victory in securing the prestigious 2025 Amgen x NSG Golden Ticket. This highly coveted award recognizes Singzyme's groundbreaking bioconjugation platform, a technology poised to redefine the future of drug discovery and therapeutic development.

The Amgen x NSG Golden Ticket is more than just an accolade; it's a launchpad for innovation.

Awarded to promising biotech startups, it grants Singzyme unparalleled access to state-of-the-art laboratory space at NSG BioLabs, along with invaluable resources and mentorship from Amgen, a global leader in biotechnology. This strategic partnership is expected to significantly accelerate Singzyme's research and development efforts, propelling their pioneering technology from concept to real-world application.

At the heart of Singzyme's success lies its proprietary bioconjugation platform.

Bioconjugation is a sophisticated process that involves chemically linking two or more biomolecules, such as proteins, antibodies, or small molecules, to create novel therapeutic entities. While this field holds immense promise, current methods often face challenges in terms of precision, efficiency, and scalability.

Singzyme's platform addresses these limitations head-on, offering a more precise, robust, and versatile approach to creating complex drug conjugates.

Dr. Wei Qiang, CEO of Singzyme, expressed his enthusiasm, stating, "Winning the Amgen x NSG Golden Ticket is a tremendous validation of our team's dedication and the transformative potential of our bioconjugation technology.

This partnership will provide us with the resources and mentorship necessary to push the boundaries of drug development, ultimately bringing safer and more effective therapies to patients worldwide."

The implications of Singzyme's breakthrough extend across various therapeutic areas. Their platform holds particular promise for the development of next-generation antibody-drug conjugates (ADCs), which are highly potent targeted therapies for cancer.

Beyond ADCs, the technology is also critical for advancing cell therapies, radiopharmaceuticals, and other novel modalities that require precise molecular assembly. By enabling the creation of highly selective and potent drug conjugates, Singzyme's technology could lead to therapies with reduced side effects and enhanced efficacy.

Dr.

Song Li, President of Amgen Asia R&D, commented on the significance of the collaboration, saying, "We are thrilled to welcome Singzyme into the Amgen x NSG ecosystem. Their innovative bioconjugation platform aligns perfectly with Amgen's commitment to scientific excellence and our mission to serve patients.

Supporting promising startups like Singzyme is vital for fostering a vibrant biotech ecosystem and accelerating the discovery of life-changing medicines."

The 2025 Amgen x NSG Golden Ticket program exemplifies a strong commitment to nurturing biotech innovation in Singapore and across Asia. Dr.

Lim Jui, CEO of NSG BioLabs, highlighted the program's impact: "Our partnership with Amgen through the Golden Ticket program is designed to empower groundbreaking startups like Singzyme. By providing them with essential infrastructure and expert guidance, we are helping to cultivate the next wave of biotech leaders who will shape the future of healthcare."

With this prestigious win, Singzyme is poised to embark on an exciting journey of accelerated growth and discovery.

Their innovative bioconjugation platform is not just a scientific achievement; it's a beacon of hope for patients seeking more effective and safer treatment options, solidifying Singapore's position as a hub for cutting-edge biomedical innovation.